Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jan 18;82(3):616–620. doi: 10.1054/bjoc.1999.0972

Diagnosis of persistent ovarian carcinoma with three-step immunoscintigraphy

P Magnani 1, F Fazio 1, C Grana 3, C Songini 1, L Frigerio 1, S Pecorelli 2, G Mangili 1, N Colombo 3, C D A Mariani 3, G Paganelli 3
PMCID: PMC2363313  PMID: 10682674

Abstract

The diagnosis of recurrent ovarian carcinoma is usually determined at surgical re-exploration since the main non-invasive diagnostic tests have low accuracy. It would be desirable to have a high accuracy non-invasive diagnostic procedure. With this aim, we have assessed the utility of three-step immunoscintigraphy. Thirty patients were intravenously injected with biotinylated monoclonal antibodies MOv18 and B72.3, followed by avidin–streptavidin injection and finally by111In-biotin. Tumour recurrences were imaged 2 h post radioactivity injection. All patients underwent surgical re-exploration 3–4 days after immunoscintigraphy; the presence of tumour in the area of immunoscintigraphic uptake was evaluated in the biopsied material. Twenty-one patients studied were true-positive, five were true-negative, four were false-positive and none was false-negative. The diagnostic accuracy, positive predictive value and negative predictive value were 87%, 84% and 100% respectively. If these findings are confirmed in a larger number of patients, we expect immunoscintigraphy to be introduced as a cost-effective procedure in the follow-up of patients who have received surgery for ovarian carcinoma, since it promises to reliably identify patients who do not require surgical re-exploration, and guide biopsies when they are indicated. © 2000 Cancer Research Campaign

Keywords: ovarian carcinoma, monoclonal antibodies, avidin–biotin

Full Text

The Full Text of this article is available as a PDF (275.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Casalini P., Luison E., Ménard S., Colnaghi M. I., Paganelli G., Canevari S. Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization. J Nucl Med. 1997 Sep;38(9):1378–1381. [PubMed] [Google Scholar]
  2. Colcher D., Esteban J., Carrasquillo J. A., Sugarbaker P., Reynolds J. C., Bryant G., Larson S. M., Schlom J. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res. 1987 Aug 1;47(15):4218–4224. [PubMed] [Google Scholar]
  3. Colombo P., Paganelli G., Magnani P., Songini C., Fazio F., Faglia G. Immunoscintigraphy with anti-chromogranin A antibodies in patients with endocrine/neuroendocrine tumors. J Endocrinol Invest. 1993 Nov;16(10):841–843. doi: 10.1007/BF03348939. [DOI] [PubMed] [Google Scholar]
  4. Copeland L. J., Vaccarello L., Lewandowski G. S. Second-look laparotomy in epithelial ovarian cancer. Obstet Gynecol Clin North Am. 1994 Mar;21(1):155–166. [PubMed] [Google Scholar]
  5. Creasman W. T., Eddy G. L. Prognostic factors in relation to second-look laparotomy in ovarian cancer. Baillieres Clin Obstet Gynaecol. 1989 Mar;3(1):183–190. doi: 10.1016/s0950-3552(89)80053-7. [DOI] [PubMed] [Google Scholar]
  6. Crippa F., Buraggi G. L., Di Re E., Gasparini M., Seregni E., Canevari S., Gadina M., Presti M., Marini A., Seccamani E. Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody. Eur J Cancer. 1991;27(6):724–729. doi: 10.1016/0277-5379(91)90174-c. [DOI] [PubMed] [Google Scholar]
  7. Dosio F., Magnani P., Paganelli G., Samuel A., Chiesa G., Fazio F. Three-step tumor pre-targeting in lung cancer immunoscintigraphy. J Nucl Biol Med. 1993 Dec;37(4):228–232. [PubMed] [Google Scholar]
  8. Gershenson D. M., Copeland L. J., Wharton J. T., Atkinson E. N., Sneige N., Edwards C. L., Rutledge F. N. Prognosis of surgically determined complete responders in advanced ovarian cancer. Cancer. 1985 Mar 1;55(5):1129–1135. doi: 10.1002/1097-0142(19850301)55:5<1129::aid-cncr2820550531>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  9. Larson S. M., Carrasquillo J. A., Colcher D. C., Yokoyama K., Reynolds J. C., Bacharach S. A., Raubitchek A., Pace L., Finn R. D., Rotman M. Estimates of radiation absorbed dose for intraperitoneally administered iodine-131 radiolabeled B72.3 monoclonal antibody in patients with peritoneal carcinomatoses. J Nucl Med. 1991 Sep;32(9):1661–1667. [PubMed] [Google Scholar]
  10. Low R. N., Carter W. D., Saleh F., Sigeti J. S. Ovarian cancer: comparison of findings with perfluorocarbon-enhanced MR imaging, In-111-CYT-103 immunoscintigraphy, and CT. Radiology. 1995 May;195(2):391–400. doi: 10.1148/radiology.195.2.7724757. [DOI] [PubMed] [Google Scholar]
  11. Magnani P., Paganelli G., Songini C., Samuel A., Sudati F., Siccardi A. G., Fazio F. Pretargeted immunoscintigraphy in patients with medullary thyroid carcinoma. Br J Cancer. 1996 Sep;74(5):825–831. doi: 10.1038/bjc.1996.443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Matzku S., Kirchgessner H., Schmid U., Temponi M., Ferrone S. Melanoma targeting with a cocktail of monoclonal antibodies to distinct determinants of the human HMW-MAA. J Nucl Med. 1989 Mar;30(3):390–397. [PubMed] [Google Scholar]
  13. Method M. W., Serafini A. N., Averette H. E., Rodriguez M., Penalver M. A., Sevin B. U. The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma. A preliminary report. Cancer. 1996 Jun 1;77(11):2286–2293. doi: 10.1002/(SICI)1097-0142(19960601)77:11<2286::AID-CNCR16>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
  14. Mezzanzanica D., Canevari S., Ménard S., Pupa S. M., Tagliabue E., Lanzavecchia A., Colnaghi M. I. Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components. Int J Cancer. 1988 Apr 15;41(4):609–615. doi: 10.1002/ijc.2910410422. [DOI] [PubMed] [Google Scholar]
  15. Miotti S., Canevari S., Ménard S., Mezzanzanica D., Porro G., Pupa S. M., Regazzoni M., Tagliabue E., Colnaghi M. I. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer. 1987 Mar 15;39(3):297–303. doi: 10.1002/ijc.2910390306. [DOI] [PubMed] [Google Scholar]
  16. Morgan M. A., Noumoff J. S., King S., Mikuta J. J. A formula for predicting the risk of a positive second-look laparotomy in epithelial ovarian cancer: implications for a randomized trial. Obstet Gynecol. 1992 Dec;80(6):944–948. [PubMed] [Google Scholar]
  17. Paganelli G., Magnani P., Zito F., Lucignani G., Sudati F., Truci G., Motti E., Terreni M., Pollo B., Giovanelli M. Pre-targeted immunodetection in glioma patients: tumour localization and single-photon emission tomography imaging of [99mTc]PnAO-biotin. Eur J Nucl Med. 1994 Apr;21(4):314–321. doi: 10.1007/BF00947966. [DOI] [PubMed] [Google Scholar]
  18. Paganelli G., Magnani P., Zito F., Villa E., Sudati F., Lopalco L., Rossetti C., Malcovati M., Chiolerio F., Seccamani E. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res. 1991 Nov 1;51(21):5960–5966. [PubMed] [Google Scholar]
  19. Peltier P., Curtet C., Chatal J. F., Le Doussal J. M., Daniel G., Aillet G., Gruaz-Guyon A., Barbet J., Delaage M. Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med. 1993 Aug;34(8):1267–1273. [PubMed] [Google Scholar]
  20. Podratz K. C., Kinney W. K. Second-look operation in ovarian cancer. Cancer. 1993 Feb 15;71(4 Suppl):1551–1558. [PubMed] [Google Scholar]
  21. Potter M. E., Hatch K. D., Soong S. J., Partridge E. E., Austin J. M., Jr, Shingleton H. M. Second-look laparotomy and salvage therapy: a research modality only? Gynecol Oncol. 1992 Jan;44(1):3–9. doi: 10.1016/0090-8258(92)90002-z. [DOI] [PubMed] [Google Scholar]
  22. Rubin S. C., Hoskins W. J., Saigo P. E., Chapman D., Hakes T. B., Markman M., Reichman B., Almadrones L., Lewis J. L., Jr Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. Gynecol Oncol. 1991 Aug;42(2):137–141. doi: 10.1016/0090-8258(91)90333-z. [DOI] [PubMed] [Google Scholar]
  23. Rubin S. C. Monoclonal antibodies in the management of ovarian cancer. A clinical perspective. Cancer. 1993 Feb 15;71(4 Suppl):1602–1612. doi: 10.1002/cncr.2820710427. [DOI] [PubMed] [Google Scholar]
  24. Seccamani E., Tattanelli M., Mariani M., Spranzi E., Scassellati G. A., Siccardi A. G. A simple qualitative determination of human antibodies to murine immunoglobulins (HAMA) in serum samples. Int J Rad Appl Instrum B. 1989;16(2):167–170. doi: 10.1016/0883-2897(89)90191-8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES